ALTSTATION.IO

GE HealthCare Technologies Inc. (GEHC) Stock Analysis

By Nova Skye | AltStation.io | Updated October 07, 2026

Price

$65.29

Change

-0.68%

Market Cap

$29.70B

Avg Volume

4.1M

Company Overview

GE HealthCare Technologies Inc. is a Chicago-based medical device company that builds the essential hardware and software hospital systems rely on to diagnose and treat patients. The business operates across four main divisions: Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics. They sell heavy-duty clinical hardware like CT scanners, MRI machines, and X-ray systems, alongside bedside patient monitors, anesthesia devices, and ultrasound equipment. They also manufacture the proprietary contrast agents and radiopharmaceuticals that radiology clinics inject into patients to make diagnostic scans readable. Their customer base is direct and institutional, spanning hospitals, diagnostic centers, and healthcare providers globally.

GE HealthCare is an entrenched top-tier player in medical devices, competing head-to-head with Siemens Healthineers and Philips. The company holds a distinct operational edge because it sells both the multi-million-dollar imaging hardware and the recurring consumable contrast agents and servicing contracts required to run them. That massive global footprint creates high switching costs for hospitals that cannot easily swap complex imaging workflows. Even so, competition is intense; Siemens Healthineers generated roughly 24 billion dollars in fiscal 2024 revenue, staying ahead of GE HealthCare’s 19.67 billion dollars and pressuring the firm to defend its market share.

Since completing its corporate separation in December 2022, GE HealthCare has performed like a steady cash-flow engine looking for its next gear. Revenue moved from 19.55 billion dollars in 2023 to 19.67 billion dollars in 2024, which translates to a sluggish top-line growth rate of under 1%. To drive higher-margin growth, the company is pivoting toward embedded healthcare software and artificial intelligence, backed by moves like its strategic collaboration with DeepHealth. GE HealthCare is a defensive powerhouse with sticky institutional revenue, but management needs to translate its digital and diagnostic pipeline into faster organic growth to keep pace with the competition.

Key Financials

Market Cap

$29.70B

Revenue

$21.27B

EBITDA

$3.59B

Gross Margin

39.5%

Profit Margin

9.3%

Revenue Growth

5.8%

Total Cash

$2.08B

Total Debt

$10.54B

Free Cash Flow

$1.57B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

15.01

Forward P/E

12.07

Beta

0.85

52-Week High

$89.77

52-Week Low

$58.75

EPS

$4.35

50-Day Avg

$68.82

200-Day Avg

$71.19

Price/Book

2.69

Technical Analysis

GEHC trades at $65.29, just 20% of the way from its $58.72 52-week low to its $89.64 high. The stock is 27.74% below that high and 10.31% above the low. Price is -0.45% versus the 20-day moving average of $65.06, putting it close to trend but without a clear breakout. Momentum is negative, with shares down 2.54% over five trading days and 3.00% over 20 trading days. Near-term support is $63.49, while $73.91 is the resistance level buyers need to clear.

Recent News and Developments

GE HealthCare schedules third-quarter earnings for October 28

GE HealthCare will release third-quarter 2026 results before the market opens on October 28. Management will hold its conference call at 8:30 a.m. Eastern Time the same day. Source: Business Wire

GE HealthCare agrees to buy SOFIE Biosciences for $945 million

GE HealthCare will pay $945 million in cash for SOFIE Biosciences, adding 15 U.S. manufacturing sites, 21 cyclotrons and U.S. rights to the Phase III FAPI-74 cancer-imaging tracer. The deal is expected to close in the first half of 2027, subject to regulatory approval. Source: GE HealthCare

Citi cuts GEHC price target to $71

Citi lowered its GE HealthCare target from $75 to $71, a 5.3% reduction, while keeping a Neutral rating. The firm cited low expectations for the third quarter but sees pockets of growth and a possible recovery in 2027. Source: TipRanks

Market Sentiment and Analyst Recommendations

Bull Case

Revenue is $21.27 billion and growing 5.8%, giving GE HealthCare a solid operating base. The stock trades at 15.01 times earnings, while the consensus analyst target of $82.79 sits well above the current $65.29 price. All 19 analysts included in the recommendation data collectively rate GEHC a buy, with targets ranging from $70.00 to $96.00. The $945 million SOFIE Biosciences acquisition adds 15 U.S. manufacturing sites, 21 cyclotrons and U.S. rights to the Phase III FAPI-74 cancer-imaging tracer. That deal gives investors a specific growth catalyst beyond the existing business. The bull case is straightforward: buy a profitable healthcare company near the lower end of its annual range before earnings and the planned expansion of its cancer-imaging capabilities.

Bear Case

GE HealthCare carries $10.54 billion in total debt against $2.08 billion in cash. Paying $945 million in cash for SOFIE Biosciences adds pressure to an already debt-heavy balance sheet. Price momentum is also weak, with losses of 2.54% over five trading days and 3.00% over 20 trading days. The acquisition rally faded quickly: GEHC rose 2.26% to $65.74 on October 5, then fell 1.48% to $64.77 on October 6. Citi cut its target from $75 to $71, a 5.3% reduction, and kept a Neutral rating because of low third-quarter expectations. The new patent-infringement complaint adds legal uncertainty, although the docket provides no damages figure.

What to Watch

Third-quarter 2026 results arrive before the market opens on October 28, followed by management’s call at 8:30 a.m. Eastern Time. Investors should compare the reported growth picture with the current 5.8% revenue-growth rate. A break below $63.49 would weaken the near-term chart, while a move above $73.91 would clear the current 30-day resistance. Watch whether analysts move closer to Citi’s $71 target or maintain the broader $82.79 consensus. The SOFIE Biosciences acquisition is expected to close in the first half of 2027, subject to regulatory approval, so approval progress matters. Investors should also monitor the patent case because the current docket identifies three patents but gives no damages figure.

Analyst Consensus

BUY

Based on 19 analyst opinions

Low Target

$70.00

Mean Target

$82.79

High Target

$96.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Devices

Employees

54,000

Earnings & Dividends

Next Earnings

Oct 28, 2026

EPS (Trailing)

$4.35

Dividend Yield

24.0%

Payout Ratio

3.2%

Frequently Asked Questions

Is GEHC a good stock to buy?

GEHC has a buy recommendation from 19 analysts, 5.8% revenue growth and a P/E ratio of 15.01. The analyst view is bullish, but the negative five-day and 20-day momentum shows the stock has not confirmed that optimism.

What is GEHC’s price target?

The consensus analyst target is $82.79, with estimates ranging from $70.00 to $96.00. The takeaway is that every listed target is above the current $65.29 price.

What is GEHC’s 52-week range?

The key data lists a 52-week range of $58.75 to $89.77, while the technical price series shows an exact low of $58.72 and high of $89.64. At $65.29, GEHC sits 20% of the way from the technical low to the high.

What are GEHC’s support and resistance levels?

Near-term support is the 30-day low of $63.49, and near-term resistance is the 30-day high of $73.91. The takeaway is that those are the main levels to track around the current $65.29 price.

Does GEHC pay a dividend?

The provided key and technical data do not include dividend information. The takeaway is that GEHC’s dividend status cannot be determined from these figures alone.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated October 07, 2026.